These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26054893)

  • 61. Efficacy and safety of insulin detemir.
    Raskin P
    Endocrinol Metab Clin North Am; 2007 Aug; 36 Suppl 1():21-32. PubMed ID: 17881329
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes.
    Chacra AR; Kipnes M; Ilag LL; Sarwat S; Giaconia J; Chan J;
    Diabet Med; 2010 May; 27(5):563-9. PubMed ID: 20536953
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States.
    Valentine WJ; Erny-Albrecht KM; Ray JA; Roze S; Cobden D; Palmer AJ
    Adv Ther; 2007; 24(2):273-90. PubMed ID: 17565917
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Observational 6-month open-label study of Japanese type 2 diabetes patients switching from NPH insulin to insulin detemir in basal-bolus regimen: 23rd article of the Japan Diabetes Clinical Data Management Study Group (JDDM23).
    Oishi M; Abe N; Yokoyama H; Kuribayashi N; Tomonaga O; Matoba K; Kobayashi M;
    J Int Med Res; 2012; 40(2):787-97. PubMed ID: 22613444
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study.
    Meneghini L; Mersebach H; Kumar S; Svendsen AL; Hermansen K
    Endocr Pract; 2011; 17(5):727-36. PubMed ID: 21550957
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.
    Rosenstock J; Davies M; Home PD; Larsen J; Koenen C; Schernthaner G
    Diabetologia; 2008 Mar; 51(3):408-16. PubMed ID: 18204830
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.
    Vague P; Selam JL; Skeie S; De Leeuw I; Elte JW; Haahr H; Kristensen A; Draeger E
    Diabetes Care; 2003 Mar; 26(3):590-6. PubMed ID: 12610006
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study.
    Meneghini L; Koenen C; Weng W; Selam JL
    Diabetes Obes Metab; 2007 Nov; 9(6):902-13. PubMed ID: 17924873
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes.
    Valentine WJ; Goodall G; Aagren M; Nielsen S; Palmer AJ; Erny-Albrecht K
    Adv Ther; 2008 Jun; 25(6):567-84. PubMed ID: 18568451
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Non-inferiority of insulin glargine versus insulin detemir on blood glucose variability in type 1 diabetes patients: a multicenter, randomized, crossover study.
    Renard E; Dubois-Laforgue D; Guerci B;
    Diabetes Technol Ther; 2011 Dec; 13(12):1213-8. PubMed ID: 21810024
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Continuous glucose monitoring in hemodialyzed patients with type 2 diabetes: a multicenter pilot study.
    Képénékian L; Smagala A; Meyer L; Imhoff O; Alenabi F; Serb L; Fleury D; Dorey F; Krummel T; Le Floch JP; Chantrel F; Kessler L
    Clin Nephrol; 2014 Oct; 82(4):240-6. PubMed ID: 25161114
    [TBL] [Abstract][Full Text] [Related]  

  • 72. An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update).
    Philis-Tsimikas A
    Expert Opin Pharmacother; 2008 Aug; 9(12):2181-95. PubMed ID: 18671472
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Spotlight on insulin detemir in type 1 and 2 diabetes mellitus.
    Chapman TM; Perry CM
    BioDrugs; 2005; 19(1):67-9. PubMed ID: 15691219
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Efficacy and safety of insulin detemir versus glargine in patients with diabetes: a systematic review and meta-analysis.
    Rezaei S; Taheri A; Taheri S; Kasirzadeh S; Fatemi B; Sorato MM
    Expert Rev Clin Pharmacol; 2022 Jun; 15(6):767-777. PubMed ID: 35579011
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Insulin detemir: a long-acting insulin product.
    Jones MC; Patel M
    Am J Health Syst Pharm; 2006 Dec; 63(24):2466-72. PubMed ID: 17158694
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparison of insulin detemir and insulin glargine on glycemic variability in patients with type 1 and type 2 diabetes.
    Tone A; Iseda I; Higuchi C; Tsukamoto K; Katayama A; Matsushita Y; Hida K; Wada J; Shikata K
    Exp Clin Endocrinol Diabetes; 2010 May; 118(5):320-4. PubMed ID: 20072962
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study.
    King AB
    Diabetes Obes Metab; 2009 Jan; 11(1):69-71. PubMed ID: 19120433
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes.
    Vora J; Caputo S; Damci T; Orozco-Beltran D; Pan C; Svendsen AL; Sølje KS; Khunti K;
    J Clin Pharm Ther; 2014 Apr; 39(2):136-43. PubMed ID: 24329524
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
    Ilag LL; Kerr L; Malone JK; Tan MH
    Clin Ther; 2007 Jun; 29(6 Pt 1):1254-70. PubMed ID: 18036388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.